MDM2 and prostate carcinoma: However, BMI1 exerts also some important oncogenic effects in prostate cancer cells through PRC1-independent mechanisms, involving direct binding to AR and consequent inhibition of MDM2-mediated AR degradation and sustained AR signaling in prostate cancer cells [591].